WO2005111077A3 - Methods for treating bone cancer pain by administering a nerve growth factor antagonist - Google Patents

Methods for treating bone cancer pain by administering a nerve growth factor antagonist Download PDF

Info

Publication number
WO2005111077A3
WO2005111077A3 PCT/US2005/011786 US2005011786W WO2005111077A3 WO 2005111077 A3 WO2005111077 A3 WO 2005111077A3 US 2005011786 W US2005011786 W US 2005011786W WO 2005111077 A3 WO2005111077 A3 WO 2005111077A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer pain
administering
growth factor
nerve growth
methods
Prior art date
Application number
PCT/US2005/011786
Other languages
French (fr)
Other versions
WO2005111077A2 (en
Inventor
David L Shelton
Patrick William Mantyh
Original Assignee
Rinat Neuroscience Corp
Univ Minnesota
David L Shelton
Patrick William Mantyh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35394727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005111077(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI200530937T priority Critical patent/SI1732949T1/en
Priority to KR1020127028119A priority patent/KR101504729B1/en
Priority to BRPI0508390A priority patent/BRPI0508390B8/en
Priority to DK05777592.6T priority patent/DK1732949T3/en
Priority to DE602005019144T priority patent/DE602005019144D1/en
Priority to JP2007507500A priority patent/JP5301152B2/en
Priority to EP05777592A priority patent/EP1732949B1/en
Priority to EP18161002.3A priority patent/EP3372614B1/en
Priority to PL05777592T priority patent/PL1732949T3/en
Priority to KR1020147030240A priority patent/KR101637908B1/en
Priority to MXPA06011463A priority patent/MXPA06011463A/en
Application filed by Rinat Neuroscience Corp, Univ Minnesota, David L Shelton, Patrick William Mantyh filed Critical Rinat Neuroscience Corp
Priority to CA2562024A priority patent/CA2562024C/en
Priority to CN2005800185064A priority patent/CN101023099B/en
Priority to AU2005243247A priority patent/AU2005243247B2/en
Priority to EP10151672.2A priority patent/EP2206728B9/en
Priority to AT05777592T priority patent/ATE456580T1/en
Priority to NZ549990A priority patent/NZ549990A/en
Publication of WO2005111077A2 publication Critical patent/WO2005111077A2/en
Publication of WO2005111077A3 publication Critical patent/WO2005111077A3/en
Priority to IL178226A priority patent/IL178226A/en
Priority to NO20065070A priority patent/NO343065B1/en
Priority to HK08101876.9A priority patent/HK1111425A1/en
Priority to IL226555A priority patent/IL226555A/en
Priority to IL250826A priority patent/IL250826B/en
Priority to NO20180735A priority patent/NO345258B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.
PCT/US2005/011786 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist WO2005111077A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
CA2562024A CA2562024C (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
CN2005800185064A CN101023099B (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
KR1020127028119A KR101504729B1 (en) 2004-04-07 2005-04-07 Pharmaceutical composotion for treating bone cancer pain by administering a nerve growth factor antagonist
AU2005243247A AU2005243247B2 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
DE602005019144T DE602005019144D1 (en) 2004-04-07 2005-04-07 METHOD FOR TREATMENT TREATMENT IN BONE CANCER DU
JP2007507500A JP5301152B2 (en) 2004-04-07 2005-04-07 Method for treating bone cancer pain by administering a nerve growth factor antagonist
EP05777592A EP1732949B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP18161002.3A EP3372614B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
PL05777592T PL1732949T3 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
KR1020147030240A KR101637908B1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
MXPA06011463A MXPA06011463A (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist.
SI200530937T SI1732949T1 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
NZ549990A NZ549990A (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
BRPI0508390A BRPI0508390B8 (en) 2004-04-07 2005-04-07 use of an anti-ngf antagonist antibody, as well as kit and pharmaceutical composition for the treatment of bone cancer pain
DK05777592.6T DK1732949T3 (en) 2004-04-07 2005-04-07 Methods for Treating Bone Cancer Pain by Administration of a Nerve Growth Factor Antagonist
EP10151672.2A EP2206728B9 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonistic antibody
AT05777592T ATE456580T1 (en) 2004-04-07 2005-04-07 METHOD FOR PAIN TREATMENT IN BONE CANCER BY ADMINISTRATION OF A NGF ANTAGONIST
IL178226A IL178226A (en) 2004-04-07 2006-09-21 Use of an anti-nerve growth factor antibody for preparation of a medicament for treating bone cancer pain
NO20065070A NO343065B1 (en) 2004-04-07 2006-11-03 Use of a nerve growth factor (NGF) antagonist for the manufacture of a medicament for the treatment of bone cancer pain in an individual, wherein the NGF antagonist is an anti-NGF antagonist antibody, anti-NGF antagonist antibody for use in the treatment of bone cancer pain in an individual. , a kit thereof for the treatment of bone cancer pain, and a pharmaceutical composition for the treatment of bone cancer pain.
HK08101876.9A HK1111425A1 (en) 2004-04-07 2008-02-21 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
IL226555A IL226555A (en) 2004-04-07 2013-05-23 Use of a nerve growth factor antagonist in the manufacture of medicaments for treating bone cancer pain
IL250826A IL250826B (en) 2004-04-07 2017-02-27 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
NO20180735A NO345258B1 (en) 2004-04-07 2018-05-29 Methods for treating bone cancer pain by administering a nerve growth factor antagonist.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56078104P 2004-04-07 2004-04-07
US60/560,781 2004-04-07
US62065404P 2004-10-19 2004-10-19
US60/620,654 2004-10-19

Publications (2)

Publication Number Publication Date
WO2005111077A2 WO2005111077A2 (en) 2005-11-24
WO2005111077A3 true WO2005111077A3 (en) 2006-04-20

Family

ID=35394727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011786 WO2005111077A2 (en) 2004-04-07 2005-04-07 Methods for treating bone cancer pain by administering a nerve growth factor antagonist

Country Status (24)

Country Link
US (5) US7425329B2 (en)
EP (3) EP1732949B1 (en)
JP (3) JP5301152B2 (en)
KR (3) KR20060135060A (en)
AT (1) ATE456580T1 (en)
AU (2) AU2005243247B2 (en)
BR (1) BRPI0508390B8 (en)
CA (1) CA2562024C (en)
DE (1) DE602005019144D1 (en)
DK (2) DK2206728T3 (en)
ES (2) ES2338344T3 (en)
HK (1) HK1111425A1 (en)
HU (1) HUE037549T2 (en)
IL (3) IL178226A (en)
MX (1) MXPA06011463A (en)
NO (2) NO343065B1 (en)
NZ (1) NZ549990A (en)
PL (2) PL2206728T3 (en)
PT (2) PT1732949E (en)
RU (1) RU2389509C2 (en)
SG (1) SG152226A1 (en)
SI (2) SI1732949T1 (en)
TW (1) TWI367101B (en)
WO (1) WO2005111077A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US8007800B2 (en) 2004-04-07 2011-08-30 Pfizer Inc. Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340849A1 (en) * 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ITRM20030601A1 (en) 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
WO2008103475A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
ME00977B (en) 2007-08-10 2012-06-20 Regeneron Pharma High affinity human antibodies to human nerve growth factor
KR20100111273A (en) * 2007-12-20 2010-10-14 사이토스 바이오테크놀로지 아게 Nerve growth factor conjugates and uses thereof
PL2252633T3 (en) 2008-02-04 2014-02-28 Lay Line Genomics Spa Anti-trka antibodies and derivatives thereof
HUE026595T2 (en) 2008-09-24 2016-06-28 Ribomic Inc Aptamer for ngf and use thereof
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
US9041541B2 (en) 2010-01-28 2015-05-26 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
US9033898B2 (en) * 2010-06-23 2015-05-19 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
EP2408369A1 (en) 2009-03-02 2012-01-25 Seventh Sense Biosystems, Inc. Devices and methods for the analysis of an extractable medium
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
WO2011118682A1 (en) 2010-03-24 2011-09-29 株式会社リボミック Aptamer for ngf and use thereof
US20120016308A1 (en) 2010-07-16 2012-01-19 Seventh Sense Biosystems, Inc. Low-pressure packaging for fluid devices
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
PL3333188T3 (en) 2010-08-19 2022-05-09 Zoetis Belgium S.A. Anti-ngf antibodies and their use
CA2816326C (en) * 2010-11-03 2020-12-15 Ethicon, Llc Drug-eluting self-retaining sutures and methods relating thereto
ES2565805T3 (en) 2010-11-09 2016-04-07 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
CA2821515A1 (en) 2010-12-01 2012-06-07 Alder Biopharmaceuticals, Inc. Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
EP2701598A1 (en) 2011-04-29 2014-03-05 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
JP2014516644A (en) 2011-04-29 2014-07-17 セブンス センス バイオシステムズ，インコーポレーテッド Devices and methods for collection and / or manipulation of blood spots or other body fluids
KR102013466B1 (en) 2011-04-29 2019-08-22 세븐쓰 센스 바이오시스템즈, 인크. Delivering and/or receiving fluids
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
CA2834983C (en) * 2011-05-06 2020-11-17 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
JP6258194B2 (en) * 2011-05-06 2018-01-10 ネックスヴェット オーストラリア プロプライエタリー リミテッド Anti-nerve growth factor antibodies and methods of making and using them
EP2800606A4 (en) * 2012-01-05 2015-07-15 Beech Tree Labs Inc Method of treating pain by administration of nerve growth factor
NZ766918A (en) 2012-01-12 2023-03-31 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
JP6629069B2 (en) 2012-06-06 2020-01-15 ゾエティス・エルエルシー Canine anti-NGF antibody and method thereof
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
NO2699580T3 (en) 2014-01-24 2018-02-24
JP2017529356A (en) 2014-09-17 2017-10-05 ムンディファーマ インターナショナル コーポレイション リミテッド Crystal forms of tyrosine kinase inhibitors and salts thereof
TWI706959B (en) * 2015-05-22 2020-10-11 日商安斯泰來製藥股份有限公司 Novel anti-human NGF antibody Fab fragment
PT3356390T (en) 2015-09-28 2021-04-21 Univ Florida Methods and compositions for antibody-evading virus vectors
EP3765499A1 (en) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
CN108623687A (en) 2018-04-17 2018-10-09 中山康方生物医药有限公司 The monoclonal antibody and its encoding gene of nerve growth factor and application
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR102259515B1 (en) 2019-11-29 2021-06-02 징검다리커뮤니케이션(주) Augmented reality system for maintenance of underground pipeline
EP4093387A4 (en) * 2020-01-24 2024-04-24 Dompe Farm Spa Growth factor formulation for condition associated with otic event
US20230158057A1 (en) * 2020-04-21 2023-05-25 Duke University Compositions and methods for the treatment of pain
WO2022232420A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20040131615A1 (en) * 2002-10-08 2004-07-08 Shelton David L. Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
WO2004058184A2 (en) * 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SU975016A1 (en) 1979-12-17 1982-11-23 Московский научно-исследовательский онкологический институт им.П.А.Герцена Analgetic composition
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1995013796A1 (en) 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4786593A (en) 1985-04-16 1988-11-22 Wistar Institute Of Anatomy And Biology Diagnostic method for detection of neural crest disease
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4777124A (en) * 1986-02-28 1988-10-11 Agfa-Gevaert, N.V. Azo dye compounds for use in a dye diffusion transfer process and photographic elements incorporating them
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IN165717B (en) 1986-08-07 1989-12-23 Battelle Memorial Institute
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU3418389A (en) 1988-03-28 1989-10-16 Regents Of The University Of California, The Nerve growth factor peptides
US4855241A (en) 1988-05-26 1989-08-08 Washington University Tumor diagnostic method
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP2539665B2 (en) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 Neurological drug
CH676786A5 (en) * 1988-10-06 1991-03-15 Lasag Ag
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ATE277193T1 (en) 1989-03-21 2004-10-15 Vical Inc EXPRESSION OF EXOGENEOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBRATES
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
EP0418590B1 (en) 1989-08-28 1997-11-19 Takeda Chemical Industries, Ltd. Antibodies, production thereof and use
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5229500A (en) 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
FR2669336B1 (en) 1990-11-20 1993-01-22 Adir NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
SE510853C2 (en) * 1991-07-01 1999-06-28 Volvo Technology Transfer Ab Bipolar battery
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ES2197145T3 (en) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL.
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
DK0605522T3 (en) 1991-09-23 2000-01-17 Medical Res Council Process for producing humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5605831A (en) 1992-01-31 1997-02-25 University Of British Columbia Human melanoma cell specific antigens and antibodies
US5719032A (en) 1992-01-31 1998-02-17 University Of British Columbia Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health Vector particles resistant to inactivation by human serum.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5459183A (en) * 1993-05-19 1995-10-17 Schuller International, Inc. Low VOC furan resins and method of reducing VOCS in furan resins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435223D1 (en) 1993-10-25 2009-09-03 Canji Inc Recombinant adenovirus vector and method of use
ES2116066T3 (en) 1993-11-23 1998-07-01 Genentech Inc ACTIVATION TEST OF THE QUINASA RECEIVER.
EP0730646A1 (en) 1993-11-23 1996-09-11 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
EP0772689B1 (en) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retroviral vectors having a reduced recombination rate
US6291247B1 (en) 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5633424A (en) * 1994-12-29 1997-05-27 Graves; Clinton G. Device and methods for plasma sterilization
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997015593A1 (en) 1995-10-25 1997-05-01 Queen's University At Kingston Neurotrophin antagonists
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
ATE424463T1 (en) 1996-05-06 2009-03-15 Oxford Biomedica Ltd RECOMBINATION-INCAPABLE RETROVIRAL VECTORS
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
GB9616105D0 (en) 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
JP2001502016A (en) * 1996-10-04 2001-02-13 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Polyester fiber
ES2257768T3 (en) 1996-10-21 2006-08-01 Nps Allelix Corp. NEUROTROPINE ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN.
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US5839780A (en) * 1997-01-31 1998-11-24 Cauffiel; Ford B. Cabinet and table assembly for use with seating apparatus
DE19732928C2 (en) 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
IT1306704B1 (en) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (en) 2000-04-13 2001-10-19 Warner Lambert Co Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain
US7022484B2 (en) 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
GB0020504D0 (en) 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
US6630500B2 (en) 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002102232A2 (en) 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
WO2003022261A1 (en) 2001-09-13 2003-03-20 Miller Kenneth E Method of alleviating pain
US20040038874A1 (en) 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
GB2393383B (en) 2002-09-24 2005-12-28 Dyson Ltd A vacuum cleaning head
EP1545615A4 (en) 2002-10-04 2006-03-01 Rinat Neuroscience Corp Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
DK1556083T3 (en) * 2002-10-08 2011-04-04 Rinat Neuroscience Corp Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US20060147932A1 (en) 2003-01-18 2006-07-06 Alun Davies Methods of screening for modulators of nerve growth factor
CA2516454A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
DE10313883A1 (en) 2003-03-27 2004-10-07 Basf Ag Additive mixture to improve the lubricity properties of mineral oil products
NZ544751A (en) 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
ES2338344T3 (en) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR.
MX2007008722A (en) 2005-01-24 2008-02-15 Cambridge Antibody Tech Specific binding members for ngf.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096458A1 (en) * 2001-05-30 2002-12-05 Genentech, Inc. Anti-ngf antibodies for the treatment of various disorders
US20040131615A1 (en) * 2002-10-08 2004-07-08 Shelton David L. Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
WO2004058184A2 (en) * 2002-12-24 2004-07-15 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HALVORSON KYLE G ET AL: "A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone", CANCER RESEARCH, vol. 65, no. 20, October 2005 (2005-10-01), pages 9426 - 9435, XP002365572, ISSN: 0008-5472 *
HONGO J-A S ET AL: "ANTIBODY BINDING REGIONS ON HUMAN NERVE GROWTH FACTOR IDENTIFIED BY HOMOLOG- AND ALANINE-SCANNING MUTAGENESIS", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 19, no. 3, 2000, pages 215 - 227, XP002951932, ISSN: 0272-457X *
JONGEN J L M ET AL: "NEUROTROPHIC FACTORS AND CANCER PAIN: THE EXPRESSION OF NGF, GDNF AND BDNF BY THE MURINE OSTEOLYTIC SARCOMA CELL LINE 2472 in vitro AND in vivo AND THEIR POTENTIAL INVOLVEMENT IN BONE CANCER PAIN.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, & 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002, pages Abstract No. 52.20 URL - http://sf, XP009060864 *
SEVCIK M A ET AL: "Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization", PAIN, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 115, no. 1-2, May 2005 (2005-05-01), pages 128 - 141, XP004844690, ISSN: 0304-3959 *
SHELTON D L ET AL: "Neurotrophins and neurotrophin antagonists as potential therapeutics", RESTORATIVE NEUROLOGY AND NEUROSCIENCE 1995 IRELAND, vol. 8, no. 1-2, 1995, pages 99 - 100, XP009060880, ISSN: 0922-6028 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655232B2 (en) 2002-12-24 2010-02-02 Pfizer Inc. Anti-NGF antibodies and methods using same
US8088384B2 (en) 2002-12-24 2012-01-03 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7655231B2 (en) 2003-02-19 2010-02-02 Pfizer Inc. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID
US8007800B2 (en) 2004-04-07 2011-08-30 Pfizer Inc. Methods for treating bone cancer pain by administering a nerve growth factor antagonist antibody
US8226951B2 (en) 2004-04-07 2012-07-24 Pfizer Inc. Methods for treating bone cancer by administering a nerve growth factor antagonist antibody
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Also Published As

Publication number Publication date
RU2006139073A (en) 2008-05-20
JP2008500970A (en) 2008-01-17
ATE456580T1 (en) 2010-02-15
NZ549990A (en) 2009-08-28
IL178226A0 (en) 2006-12-31
DK2206728T3 (en) 2018-04-23
KR20120123621A (en) 2012-11-08
SG152226A1 (en) 2009-05-29
EP2206728B9 (en) 2018-10-10
NO20065070L (en) 2006-11-03
DK1732949T3 (en) 2010-04-06
IL250826A0 (en) 2017-04-30
ES2665758T3 (en) 2018-04-27
PT1732949E (en) 2010-03-23
IL226555A0 (en) 2013-06-27
BRPI0508390A (en) 2007-08-07
IL250826B (en) 2018-11-29
RU2389509C2 (en) 2010-05-20
AU2012203200B2 (en) 2014-06-26
ES2338344T3 (en) 2010-05-06
EP1732949B1 (en) 2010-01-27
JP2012229238A (en) 2012-11-22
KR20060135060A (en) 2006-12-28
US20090252744A1 (en) 2009-10-08
US8226951B2 (en) 2012-07-24
ES2665758T9 (en) 2019-02-01
SI1732949T1 (en) 2010-05-31
PL1732949T3 (en) 2010-06-30
JP5706853B2 (en) 2015-04-22
US20050265994A1 (en) 2005-12-01
IL178226A (en) 2013-07-31
US7425329B2 (en) 2008-09-16
PL2206728T3 (en) 2018-07-31
BRPI0508390B1 (en) 2020-12-22
CA2562024C (en) 2014-05-27
TWI367101B (en) 2012-07-01
CA2562024A1 (en) 2005-11-24
IL226555A (en) 2017-03-30
AU2005243247B2 (en) 2012-03-01
MXPA06011463A (en) 2007-04-25
KR101637908B1 (en) 2016-07-11
DE602005019144D1 (en) 2010-03-18
EP3372614A1 (en) 2018-09-12
US20080081040A1 (en) 2008-04-03
BRPI0508390B8 (en) 2021-05-25
JP5301152B2 (en) 2013-09-25
SI2206728T1 (en) 2018-07-31
EP2206728A1 (en) 2010-07-14
TW200603830A (en) 2006-02-01
NO20180735A1 (en) 2006-11-03
KR20140133952A (en) 2014-11-20
JP5692732B2 (en) 2015-04-01
US20110243961A1 (en) 2011-10-06
AU2005243247A1 (en) 2005-11-24
EP3372614B1 (en) 2022-06-08
WO2005111077A2 (en) 2005-11-24
JP2013209408A (en) 2013-10-10
KR101504729B1 (en) 2015-03-19
AU2012203200A1 (en) 2012-06-21
NO343065B1 (en) 2018-10-22
US8557245B2 (en) 2013-10-15
EP2206728B1 (en) 2018-03-14
US8007800B2 (en) 2011-08-30
EP1732949A2 (en) 2006-12-20
US20120315271A1 (en) 2012-12-13
PT2206728T (en) 2018-04-17
NO345258B1 (en) 2020-11-23
HUE037549T2 (en) 2018-09-28
HK1111425A1 (en) 2008-08-08

Similar Documents

Publication Publication Date Title
WO2005111077A3 (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2004032870A3 (en) Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
WO2004073653A8 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2005019266A3 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2006110883A8 (en) Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
ZA200701656B (en) Humanized anti-cment antagonists
MX349188B (en) Sns-595 and methods of using the same.
EP1771188A4 (en) Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2005077353A8 (en) Dichloroacetate in combination with an inotrope for cardioprotection
TW200614997A (en) Leaf juice of plectranthus amboinicus for treating cancer and/or tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005243247

Country of ref document: AU

Ref document number: 549990

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 178226

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200608177

Country of ref document: ZA

Ref document number: 2562024

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/011463

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12006501970

Country of ref document: PH

Ref document number: 2007507500

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 06103017

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2005243247

Country of ref document: AU

Date of ref document: 20050407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005243247

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005777592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6473/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020067023106

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006139073

Country of ref document: RU

Ref document number: 1200601827

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200580018506.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005777592

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067023106

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0508390

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 226555

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 250826

Country of ref document: IL